Physician profile
Eliot B Hoffman
NPI 1417952300
$18,972.97
in general payments reported to CMS, 2019-2025
35 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $2,432 · 2021: $3,915 · 2022: $3,360 · 2023: $3,480 · 2024: $2,673 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,777 · Education: $23.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,777.37 |
| Education | $23.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $4,270.36 | 2020-2025 | Barostim Neo System |
| Abbott Laboratories | $3,126.59 | 2019-2025 | Aveir, Merlin@Home, Jot Dx |
| Janssen Pharmaceuticals, INC | $1,390.93 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,336.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,168.56 | 2019-2025 | Jardiance |
| Amgen INC. | $1,050.00 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $771.20 | 2019-2025 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $710.10 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $690.74 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $677.86 | 2019-2025 | |
| Philips North America LLC | $376.99 | 2020-2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und, (Ck7) Extended Holter |
| Novo Nordisk INC | $347.49 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $347.29 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $296.66 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $280.80 | 2019-2023 | Livalo |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliot Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.